Literature DB >> 12106904

Protein aggregation in Huntington's disease.

Guylaine Hoffner1, Philippe Djian.   

Abstract

The presence of an expanded polyglutamine produces a toxic gain of function in huntingtin. Protein aggregation resulting from this gain of function is likely to be the cause of neuronal death. Two main mechanisms of aggregation have been proposed: hydrogen bonding by polar-zipper formation and covalent bonding by transglutaminase-catalyzed cross-linking. In cell culture models of Huntington's disease, aggregates are mostly stabilized by hydrogen bonds, but covalent bonds are also likely to occur. Nothing is known about the nature of the bonds that stabilize the aggregates in the brain of patients with Huntington's disease. It seems that the nature of the bond stabilizing the aggregates is one of the most important questions, as the answer would condition the therapeutic approach to Huntington's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12106904     DOI: 10.1016/s0300-9084(02)01398-6

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  12 in total

1.  Protein thermal aggregation involves distinct regions: sequential events in the heat-induced unfolding and aggregation of hemoglobin.

Authors:  Yong-Bin Yan; Qi Wang; Hua-Wei He; Hai-Meng Zhou
Journal:  Biophys J       Date:  2004-03       Impact factor: 4.033

Review 2.  Huntington's disease: can mice lead the way to treatment?

Authors:  Zachary R Crook; David Housman
Journal:  Neuron       Date:  2011-02-10       Impact factor: 17.173

Review 3.  Polyglutamine Aggregation in Huntington Disease: Does Structure Determine Toxicity?

Authors:  Guylaine Hoffner; Philippe Djian
Journal:  Mol Neurobiol       Date:  2014-10-22       Impact factor: 5.590

4.  Amitriptyline improves motor function via enhanced neurotrophin signaling and mitochondrial functions in the murine N171-82Q Huntington disease model.

Authors:  Wei-Na Cong; Wayne Chadwick; Rui Wang; Caitlin M Daimon; Huan Cai; Jennifer Amma; William H Wood; Kevin G Becker; Bronwen Martin; Stuart Maudsley
Journal:  J Biol Chem       Date:  2014-12-11       Impact factor: 5.157

Review 5.  Current and Possible Future Therapeutic Options for Huntington's Disease.

Authors:  Mackenzie W Ferguson; Connor J Kennedy; Thulani H Palpagama; Henry J Waldvogel; Richard L M Faull; Andrea Kwakowsky
Journal:  J Cent Nerv Syst Dis       Date:  2022-05-21

Review 6.  Aggregation of expanded huntingtin in the brains of patients with Huntington disease.

Authors:  Guylaine Hoffner; Sylvie Souès; Philippe Djian
Journal:  Prion       Date:  2007 Jan-Mar       Impact factor: 3.931

7.  Effects of urea and acetic acid on the heme axial ligation structure of ferric myoglobin at very acidic pH.

Authors:  Enrica Droghetti; Suganya Sumithran; Masanori Sono; Marián Antalík; Milan Fedurco; John H Dawson; Giulietta Smulevich
Journal:  Arch Biochem Biophys       Date:  2009-07-19       Impact factor: 4.013

8.  Two-dimensional infrared correlation spectroscopy study of sequential events in the heat-induced unfolding and aggregation process of myoglobin.

Authors:  Yong-Bin Yan; Qi Wang; Hua-Wei He; Xin-Yao Hu; Ri-Qing Zhang; Hai-Meng Zhou
Journal:  Biophys J       Date:  2003-09       Impact factor: 4.033

Review 9.  Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease.

Authors:  Gary X D'Souza; Henry J Waldvogel
Journal:  J Huntingtons Dis       Date:  2016-12-15

10.  Metabolic states following accumulation of intracellular aggregates: implications for neurodegenerative diseases.

Authors:  Alexei Vazquez
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.